5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Invited conference paper presented and published in conference proceedings
全文
替代計量分析
.
其它資訊
著者Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S-W., Ursol G., Hussein M., Lim F.L., Yang C-T., Araujo L.H., Saito H., Reinmuth N., Medic N., Mann H., Shi X., Peters S., Mok T.S.K., Johnson M.
會議名稱European Lung Cancer Congress (ELCC) 2022
會議開始日30.03.2022
會議完結日02.04.2022
會議地點Virtual
會議國家/地區瑞士
會議論文集題名Annals of Oncology
詳細描述European Lung Cancer Congress (ELCC) 2022, 30 March-2 April 2022
出版年份2022
月份4
卷號33
期次Suppl 2
頁次S29 - S30
國際標準期刊號0923-7534
語言英式英語
